Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Total Liabilities
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd total liabilities. Based on the latest financial reports, Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (300534) has total liabilities worth CN¥516.44 Million CNY (≈ $75.57 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Gansu Longshenrongfa Pharmaceutical Indu liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2025)
Total liabilities of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025. This chart illustrates how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Gansu Longshenrongfa Pharmaceutical Indu to see how much of total assets are deployed in long-term investments.
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Competitors by Total Liabilities
The table below lists competitors of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Talent Television&Film Co Ltd
SHE:300426
|
China | CN¥1.63 Billion |
|
Qingdao Vland Biotech Co Ltd
SHG:603739
|
China | CN¥1.14 Billion |
|
Intrepid Potash Inc
NYSE:IPI
|
USA | $134.73 Million |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
India | Rs40.16 Billion |
|
Zhengyuan Geomatics Group Co Ltd
SHG:688509
|
China | CN¥1.89 Billion |
|
Aeris Resources Ltd
AU:AIS
|
Australia | AU$326.12 Million |
|
Cimentas Izmir Cimento Fabrikasi TAS
IS:CMENT
|
Turkey | TL5.93 Billion |
|
Bohus ASA
OL:BOHUS
|
Norway | Nkr2.71 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Gansu Longshenrongfa Pharmaceutical Indu.
Liquidity & Leverage Metrics
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd Total Liabilities Ratios Explained
Gansu Longshenrongfa Pharmaceutical Industry Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Gansu Longshenrongfa Pharmaceutical Industry Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Gansu Longshenrongfa Pharmaceutical Industry Co Ltd (2011–2025)
The table below shows the annual total liabilities of Gansu Longshenrongfa Pharmaceutical Industry Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥613.42 Million ≈ $89.76 Million |
-9.04% |
| 2024-12-31 | CN¥674.39 Million ≈ $98.68 Million |
+7.88% |
| 2023-12-31 | CN¥625.14 Million ≈ $91.48 Million |
+317.70% |
| 2022-12-31 | CN¥149.66 Million ≈ $21.90 Million |
+64.03% |
| 2021-12-31 | CN¥91.24 Million ≈ $13.35 Million |
-28.46% |
| 2020-12-31 | CN¥127.53 Million ≈ $18.66 Million |
+78.96% |
| 2019-12-31 | CN¥71.26 Million ≈ $10.43 Million |
+23.54% |
| 2018-12-31 | CN¥57.68 Million ≈ $8.44 Million |
-17.64% |
| 2017-12-31 | CN¥70.04 Million ≈ $10.25 Million |
+17.24% |
| 2016-12-31 | CN¥59.74 Million ≈ $8.74 Million |
-75.23% |
| 2015-12-31 | CN¥241.17 Million ≈ $35.29 Million |
+108.99% |
| 2014-12-31 | CN¥115.40 Million ≈ $16.89 Million |
-14.54% |
| 2013-12-31 | CN¥135.04 Million ≈ $19.76 Million |
+9.73% |
| 2012-12-31 | CN¥123.07 Million ≈ $18.01 Million |
+63.77% |
| 2011-12-31 | CN¥75.15 Million ≈ $11.00 Million |
-- |
About Gansu Longshenrongfa Pharmaceutical Industry Co Ltd
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD researches, develops, produces, and sells traditional Chinese medicines, medical devices, and health products in China and internationally. It is also involved in the cultivation, processing, and sales of chemical drugs and medicinal herbs, as well as pharmaceutical distribution, testing, and inspection services. The company was founded in 2002… Read more